Barclays PLC Acquires 151,458 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Barclays PLC lifted its holdings in shares of Humacyte, Inc. (NASDAQ:HUMA) by 177.6% during the third quarter, HoldingsChannel reports. The firm owned 236,742 shares of the company’s stock after purchasing an additional 151,458 shares during the quarter. Barclays PLC’s holdings in Humacyte were worth $1,288,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in Humacyte by 9.6% during the third quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares during the period. XTX Topco Ltd grew its position in shares of Humacyte by 48.8% in the third quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock valued at $185,000 after purchasing an additional 11,172 shares in the last quarter. Insigneo Advisory Services LLC bought a new stake in shares of Humacyte during the 3rd quarter valued at $109,000. Wellington Management Group LLP grew its holdings in Humacyte by 30.9% during the 3rd quarter. Wellington Management Group LLP now owns 254,411 shares of the company’s stock valued at $1,384,000 after buying an additional 60,087 shares in the last quarter. Finally, State Street Corp raised its position in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 over the last 90 days. 11.20% of the stock is owned by insiders.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.61 on Monday. The business’s 50-day moving average is $4.67 and its 200 day moving average is $5.69. Humacyte, Inc. has a 12 month low of $2.48 and a 12 month high of $9.97. The company has a market capitalization of $580.21 million, a P/E ratio of -3.44 and a beta of 1.32. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61.

Analyst Ratings Changes

HUMA has been the subject of a number of research reports. Benchmark boosted their price target on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, December 23rd. Piper Sandler set a $6.00 target price on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. BTIG Research restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Humacyte presently has a consensus rating of “Buy” and a consensus price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.